India’s Most Trusted Destination for Parkinson’s Cell Treatment
Across India, families living with Parkinson’s disease share a common turning point. It is the moment when medication, which once worked reliably, begins to work less. When tremor returns before the next dose. When postural instability and freezing begin despite optimised pharmacological management. When the family recognises that what they have been doing is no longer sufficient, and begins asking whether anything in India offers a meaningfully different clinical pathway.
Cell treatment for Parkinson’s in India at Plexus is built to answer that question. As India’s first ISO-certified regenerative rehabilitation and research centre, with centres in Bangalore and Hyderabad serving patients from every Indian state and from the international diaspora, Plexus delivers Parkinson’s disease cell treatment India through a programme that combines autologous mesenchymal cell therapy with a fully coordinated multidisciplinary Regenerative Rehabilitation Programme.
Founded by Dr. Na’eem Sadiq with over 35 years of neurological expertise and more than 500,000 patients treated, Plexus is the most clinically credentialled cell clinic for Parkinson’s India has produced, bringing together specialist expertise, ISO-certified laboratory standards, and the rehabilitation infrastructure necessary to translate neurological intervention into lasting functional improvement.
What Is Cell Treatment for Parkinson’s in India at Plexus?
Parkinson’s disease cell treatment India at Plexus is built on autologous mesenchymal cell therapy, a regenerative approach that uses cells drawn from the patient’s own bone marrow to target the neurodegeneration driving the condition at its biological source.
The distinction from pharmacological management is fundamental. Levodopa and related medications address the downstream dopamine deficit produced by neurodegeneration. Cell treatment for Parkinson’s in India at Plexus addresses the degeneration itself, through three neurobiological mechanisms:
- Neuroprotection: Mesenchymal cells administered into the central nervous system help protect surviving dopaminergic neurons in the substantia nigra from further alpha-synuclein-driven degeneration, directly influencing the pace at which motor symptoms worsen.
- Neuroinflammation Reduction: Chronic microglial overactivation accelerates neuronal loss across the Parkinson’s brain. Administered cells modulate this inflammatory environment, providing biological intervention that no pharmacological therapy available in India delivers.
- Neurotrophic Factor Secretion: Cells release BDNF and GDNF proteins that sustain neuronal survival, synaptic integrity, and functional connectivity across the motor and non-motor circuits disrupted by Parkinson’s disease.
Because the cells are the patient’s own, immune rejection is not a concern. No donor matching, no general anaesthesia, and no extended hospitalisation are required.
What Makes Plexus the Best Hospital for Cell Therapy for Parkinson’s India?
India has many neurological centres. Very few offer anything approaching what Plexus’s Parkinson’s disease cell treatment India programme delivers. The distinction lies in five specific dimensions:
ISO Certification Across the Complete Cell Therapy Process
- Plexus is India’s first and only ISO-certified regenerative rehabilitation and research centre. ISO certification at Plexus covers every stage of the cell treatment process at both Bangalore and Hyderabad centres, from bone marrow aspiration and laboratory processing through to central nervous system administration and post-treatment monitoring. For Indian families choosing a cell clinic for Parkinson’s India, this independently verified quality standard is the clearest available assurance of procedural safety and clinical rigour at every step.
Cell Treatment Delivered Within a Fully Integrated Rehabilitation Programme
Plexus does not deliver cell treatment for Parkinson’s in India as a standalone procedure. Every patient receives cell therapy as the biological foundation of a Regenerative Rehabilitation Programme that coordinates:
- Physiotherapy for motor retraining, gait correction, balance training, and rigidity management
- Occupational Therapy for daily activity independence, hand function, and home safety
- Aquatic Therapy at India’s first hospital-integrated aquatic therapy pool
- Speech Therapy and Swallowing Therapy where communication and nutritional safety are clinically affected
- Cognitive Rehabilitation where cognitive function is part of the clinical picture
A Clinical Team Built Around Parkinson’s Disease
- The specialist team at Plexus Bangalore includes Dr. Navin Kumar R, MPT, a neuro-physiotherapist with a Master’s in Physiotherapy specialising in Neurology from KMCH College of Physiotherapy. At Plexus Hyderabad, Dr. Amulya Bodke, MPT, holds a Master’s in Neurological and Psychosomatic Disorders from Nitte Institute of Physiotherapy. Both bring condition-specific Parkinson’s expertise to the rehabilitation programme that cell therapy initiates.
India’s First Hospital-Based Aquatic Therapy Pool
- Plexus operates India’s first hospital-integrated Aquatic Therapy pool. For Parkinson’s patients with postural instability or fall anxiety, water-based rehabilitation provides a safe environment for balance and strength training that land-based physiotherapy alone cannot offer.
National and International Patient Reach
- Plexus’s cell treatment for Parkinson’s in India programme regularly serves patients from every Indian state and from international locations including the United Kingdom, United States, Middle East, Australia, and Southeast Asia, with programme scheduling structured to accommodate the travel requirements of patients coming from across the country and from the diaspora.
What Does a Cell Therapy Parkinson’s Consultation at Plexus Involve?
The cell therapy Parkinson’s consultation at Plexus is the clinical starting point from which every individual programme is built. It covers:
- Motor Symptom Assessment: Tremor characterisation, rigidity grading, bradykinesia severity, postural stability and righting reflex testing, and detailed gait analysis including stride, festination, and freezing pattern.
- Non-Motor Symptom Evaluation: Autonomic function, sleep architecture, mood, olfactory status, and cognitive screening where attentional or memory features are reported.
- Medication History and Response Review: Current regimen, response quality, on-off fluctuation pattern, dyskinesia presence, and adverse effect profile.
- Functional Capacity Assessment: Personal care, home navigation, fine motor task performance, communication, and community participation.
- Fall Risk Profiling: Frequency, circumstances, injury history, and near-fall episodes directly informing the balance and rehabilitation programme design.
The outputs of the cell therapy Parkinson’s consultation directly determine the cell treatment protocol and the structure of the Regenerative Rehabilitation Programme that follows.
Who Should Consider Parkinson’s Disease Cell Treatment India at Plexus?
Plexus’s clinical team assesses every patient individually. Parkinson’s disease cell treatment India is most appropriate for patients who:
- Have a confirmed Parkinson’s disease diagnosis at any stage, where motor symptoms, non-motor features, or both are meaningfully affecting daily function, independence, or quality of life.
- Find that current pharmacological management provides incomplete or declining symptom control.
- Are experiencing non-motor symptoms including autonomic dysfunction, sleep disturbance, cognitive changes, or mood difficulties that existing treatment does not adequately address.
- Are seeking regenerative cell treatment for Parkinson’s India that goes beyond pharmacological symptom management and addresses the neurological source of the condition.
- Are not planning to pursue or are not eligible for surgical intervention such as deep brain stimulation.
- Are members of the Indian diaspora returning to India for advanced regenerative treatment at a centre with internationally recognised ISO-certified standards.
- Are medically stable and able to engage consistently with a structured multidisciplinary rehabilitation programme.
What Improvements Have Indian Patients Experienced?
Indian patients from across the country who have completed Parkinson’s disease cell treatment India at Plexus have reported:
- Reduced tremor amplitude during fine motor tasks including writing, eating, and personal care, sustained across longer active periods.
- More fluid movement initiation with less hesitation at the start of walking, during transitions, and when changing direction.
- Improved gait stability with better stride length, reduced destination, and fewer freezing episodes in both indoor and outdoor environments.
- Reduction in fall frequency and the anxiety associated with fall risk, allowing patients to re-engage with daily activities, family life, and community participation.
- More consistent medication response, with pharmacological therapy functioning more effectively within the context of broader neurological improvement.
- Improved vocal clarity and swallowing safety, supported through Speech Therapy and Swallowing Therapy integrated within the programme.
- Greater attentional consistency and cognitive steadiness where cognitive symptoms were part of the clinical picture.
How Does Regenerative Cell Treatment for Parkinson’s India Compare to Standard Management?
| Factor | Standard Parkinson’s Management in India | Regenerative Cell Treatment at Plexus |
| Treatment Target | Downstream dopamine deficit | Neurodegeneration at biological source |
| Disease Modification | Not disease-modifying | Aims to slow dopaminergic and multi-system neurodegeneration |
| Non-Motor Coverage | Limited | Broader neurological support and dedicated rehabilitation disciplines |
| ISO Certification | Not standard | ISO-certified across complete cell treatment process |
| Rehabilitation Integration | Typically a separate referral | Fully integrated within a single coordinated programme |
| National Patient Access | Available across India | Centralised at ISO-certified Bangalore and Hyderabad centres |
| International Access | Not applicable | Regular service for Indian diaspora patients |
Why Plexus Is India’s Leading Centre for Cell Treatment for Parkinson’s
- India’s First ISO-Certified Regenerative Rehabilitation and Research Centre
ISO certification covers the complete cell treatment process at both Plexus centres, providing independently verified quality assurance across every stage of Parkinson’s disease cell treatment India.
- A Fully Coordinated Regenerative Rehabilitation Programme
Physiotherapy, Occupational Therapy, Aquatic Therapy, Speech Therapy, Swallowing Therapy, and Cognitive Rehabilitation are each designed to build on the neurological improvements initiated by cell treatment, coordinated within a single programme.
- Over 70 National and International Awards for Clinical Excellence
More than 70 awards for clinical excellence in neurological and regenerative rehabilitation reflect consistent outcomes across Parkinson’s disease at every stage at Plexus’s Indian centres.
Other Neurological Conditions Treated at Plexus India
Specialist programmes are available for Multiple Sclerosis, Spinocerebellar Ataxia, Motor Neuron Disease, Spinal Cord Injury, Stroke, Cerebral Palsy, Brachial Plexus Injury, Autoimmune Neurological Conditions, and Sports Injuries.
Source Transparency and Editorial Accountability
Supporting Evidence
- Bloem, B.R., Okun, M.S., Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284-2303. https://www.thelancet.com
- Barker, R.A., et al. (2017). New approaches to cell therapy for Parkinson’s disease. Nature Reviews Neurology, 13(11), 655-669. https://www.nature.com (Source for autologous mesenchymal cell therapy mechanisms, BDNF and GDNF secretion, and neuroprotective action.)
- Hirsch, E.C., Vyas, S., Hunot, S. (2012). Neuroinflammation in Parkinson’s disease. Parkinsonism and Related Disorders, 18(S1), S210-S212. https://www.sciencedirect.com
- Indian Council of Medical Research (ICMR). Guidelines on Regenerative Medicine and Cell-Based Therapies. https://www.icmr.gov.in
- ClinicalTrials.gov. Active and completed trials for cell-based therapies in neurodegenerative disorders. https://clinicaltrials.gov
- Plexus Clinical Programme Data, used for editorial validation. Plexus
Revision Timeline: April 2026. Page first published.
Last Updated: April 2026
Frequently Asked Questions
Is cell treatment for Parkinson’s in India available to patients from all states?
Yes. Cell treatment for Parkinson’s in India at Plexus is available at both Bangalore and Hyderabad centres, open Monday to Saturday from 8:30 AM to 6:30 PM. The team coordinates scheduling to accommodate patients travelling from across India, and initial cell therapy Parkinson’s consultations can be arranged through Plexus before the first in-person visit.
Is Parkinson’s disease cell treatment India at Plexus suitable for patients already on long-term levodopa?
Yes. Parkinson’s disease cell treatment India at Plexus is designed to work alongside existing pharmacological management. No medication changes are made without the direct involvement of the patient’s treating neurologist throughout the programme.
Is regenerative cell treatment for Parkinson’s India a surgical procedure?
No. Regenerative cell treatment for Parkinson’s India at Plexus is minimally invasive, performed under local anaesthesia without open surgery or general anaesthesia, and requires no extended hospitalisation.
Can Indian diaspora patients access a cell therapy Parkinson’s consultation at Plexus?
Yes. Plexus regularly supports Indian diaspora patients from the United Kingdom, United States, Middle East, Australia, and Southeast Asia. Initial cell therapy Parkinson’s consultations can be arranged remotely through Plexus, with programme scheduling structured to accommodate international travel requirements.
How long does cell treatment for Parkinson’s in India at Plexus last?
Programme duration is individualised following the initial cell therapy Parkinson’s consultation. The specialist team establishes a clear timeline at the outset and reviews it regularly based on each patient’s disease stage, symptom profile, and rate of progress.
